Skip to main content
SpringerLink
Log in

Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts

  • Perspectives
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

A Correction to this article was published on 03 December 2021

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Change history

References

  1. Vitti TG, Banes D, Byers TE. Bioavailability of Digoxin. N Engl J Med. 1971;285:1433. https://doi.org/10.1056/nejm197112162852512.

    Article  CAS  PubMed  Google Scholar 

  2. Bochner F, Hooper W, Tyrer J, Eadie M. The explanation of the 1968 Australian outbreak of diphenylhydantoin intoxication. Proc Aust Assoc Neurol. 1973;9:165–70.

    CAS  PubMed  Google Scholar 

  3. Glazko AJ, Kinkel AW, Alegnani WC, Holmes EL. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol Ther. 1968;9:472–548. https://doi.org/10.1002/cpt196894472.

    Article  CAS  PubMed  Google Scholar 

  4. US Food and Drug Administration, Code of Federal Regulations Title 21, 5 Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products. 1971. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.21.

  5. Macheras P. On an unphysical hypothesis of Bateman equation and its implications for pharmacokinetics. Pharm Res. 2019;36:94. https://doi.org/10.1007/s11095-019-2633-4.

    Article  CAS  PubMed  Google Scholar 

  6. Macheras P, Chryssafidis P. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts. Pharm Res. 2020;37:187. https://doi.org/10.1007/s11095-020-02894-w. Erratum: Macheras P, Chryssafidis P, Correction to: Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts. Pharm Res. 2020;37:206. https://doi.org/10.1007/s11095-020-02935-4.

  7. Chryssafidis P, Tsekouras AA, Macheras P. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. Pharm Res. 2021;38(8):1345–56. https://doi.org/10.1007/s11095-021-03078-w.

    Article  CAS  PubMed  Google Scholar 

  8. Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49:679–98. https://doi.org/10.1016/j.ejps.2013.05.019.

    Article  CAS  PubMed  Google Scholar 

  9. Neuhoff S, Rowland Yeo K, Barter Z, Jamei M, Turner D, Rostami-Hodjegan A. Application of permeability-limited physiologically-based pharmacokinetic models: Part I - Digoxin pharmacokinetics incorporating P-glycoproteinmediated efflux. J Pharm Sci. 2013;102:3145–60. https://doi.org/10.1002/jps.23594.

    Article  CAS  PubMed  Google Scholar 

  10. Neuhoff S, Rowland Yeo K, Barter Z, Jamei M, Turner D, Rostami-Hodjegan A. Application of permeability‐limited physiologically-based pharmacokinetic models: Part II-prediction of p‐glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci. 2013;102(9):3161–73. https://doi.org/10.1002/jps.23607.

    Article  CAS  PubMed  Google Scholar 

  11. Sanchez N, Sheiner LB, Halkin H, Melmon KL. Pharmacokinetics of Digoxin: Interpreting Bioavailability. Br Med J. 1973;4:132. https://doi.org/10.1136/bmj.4.5885.132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Center for Drug Evaluation and Research, Digoxin Bioequivalency Review 76268. 2002. https://www.accessdata.fda.gov/drugsatfda_docs/anda/2002/76268_Digoxin_Bioeqr.pdf.

  13. Lovering EG, McGilveray IJ, McMillan I, Tostowaryk W. Comparative Bioavailabilities from Truncated Blood Level Curves. J Pharm Sci. 1975;64:1521–4. https://doi.org/10.1002/jps.2600640921.

    Article  CAS  PubMed  Google Scholar 

  14. Abuhelwa AY, Foster DJR, Upton RN. A quantitative review and meta-models of the variability and factors affecting Oral Drug absorption-part II: gastrointestinal transit time. AAPS J. 2016;18:1322–33. https://doi.org/10.1208/s12248-016-9953-7.

    Article  CAS  PubMed  Google Scholar 

  15. Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol. 1991;29:394–9.

    CAS  PubMed  Google Scholar 

  16. Chen ML. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res. 1992;9:1380–5. https://doi.org/10.1023/A:1015842425553.

    Article  CAS  PubMed  Google Scholar 

  17. Chen ML, Davit B, Lionberger R, Wahba Z, Ahn H-Y, Yu LX. Using partial area for evaluation of bioavailability and bioequivalence. Pharm Res. 2011;28:1939–47. https://doi.org/10.1007/s11095-011-0421-x.

    Article  CAS  PubMed  Google Scholar 

  18. Macheras P, Symillides M, Reppas C. An improved intercept method for the assessment of absorption rate in bioequivalence studies. Pharm Res. 1996;13:1755–8. https://doi.org/10.1023/A:1016421630290.

    Article  CAS  PubMed  Google Scholar 

  19. Macheras P, Symillides M, Reppas C. The cutoff time point of the partial area method for assessment of rate of absorption in bio-equivalence studies. Pharm Res. 1994;11:831–4. https://doi.org/10.1023/A:1018921622981.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the anonymous reviewers for their constructive critique. Panos Macheras will use this paper as a plea for the minister of education of Greece to allow emeriti professors supervise undergraduates, MSc and PhD students after obligatory retirement.

Author information

Authors and Affiliations

  1. Department of Chemistry, Laboratory of Physical Chemistry, National and Kapodistrian University of Athens, Athens, Greece

    Athanasios A. Tsekouras

  2. PharmaInformatics Unit, Research Center ATHENA, Athens, Greece

    Athanasios A. Tsekouras & Panos Macheras

  3. Faculty of Pharmacy, Laboratory of Biopharmaceutics Pharmacokinetics, National and Kapodistrian University of Athens, Athens, Greece

    Panos Macheras

Authors
  1. Athanasios A. Tsekouras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panos Macheras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panos Macheras.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The references in the article have been renumbered and the reference list has been updated.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsekouras, A.A., Macheras, P. Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts. Pharm Res 38, 1635–1638 (2021). https://doi.org/10.1007/s11095-021-03121-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-021-03121-w

Search

Navigation